Extavia® (interferon beta-1b)
Novartis Pharmaceuticals Corp.
- Administered by subcutaneous injection every
other day; dose is 250 mcg.
- Approved for relapsing forms of MS and for
individuals with CIS.
- Extavia is an interferon beta-1b that is
biologically identical to Betaseron and made in
an identical process, but marketed by a different
company. It was released in early 2010.
- Extavia shares all prescribing, side effect, and
safety information with Betaseron. The two
pharmaceutical companies manage the patient support
programs differently; prices and
copayments may also vary. The latest information
is available through the patient-support
programs at these two companies. For more
information, visit www.mymsaa.org, and
select "About MS," and "Sources of Information."